Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis
Files
(Published version)
Date
2016
Authors
Rao, S.
Prestidge, C.A.
Miesel, L.
Sweeney, D.F.
Shinabarger, D.L.
Boulos, R.A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Antibiotics, 2016; 69(12):879-884
Statement of Responsibility
Conference Name
Abstract
Antibiotic-resistant bacteria is a major threat to human health and is predicted to become the leading cause of death from disease by 2050. Despite the recent resurgence of research and development in the area, few antibiotics have reached the market, with most of the recently approved antibiotics corresponding to new uses for old antibiotics, or structurally similar derivatives thereof. We have recently reported an in silico approach that led to the design of an entirely new class of antibiotics for the bacteria-specific mechanosensitive ion channel of large conductance: MscL. Here, we present the preclinical development of one such antibiotic, Ramizol, a first generation antibiotic belonging to that class. We present the lack of interaction between Ramizol and other mammalian channels adding credibility to its MscL selectivity. We determine the pharmacokinetic profile in a rat model and show <0.1% of Ramizol is absorbed systemically. We show this non-systemic nature of the antibiotic translates to over 70% survival of hamsters in a Clostridium difficile colitis model. Lastly, initial in vitro data indicate that resistance to Ramizol occurs at a low frequency. In conclusion, we establish the potential of Ramizol as an effective new treatment for C. difficile associated disease.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supplementary information, http://www.nature.com/ja/journal/vaop/ncurrent/extref/ja201645x1.docx
Access Status
Rights
Copyright 2016 Nature Publishing This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by nc-nd/4.0/ (http://creativecommons.org/licenses/by nc-nd/4.0/)